NGENNasdaqPharmaceutical PreparationsFiscal year ends December 31
NERVGEN PHARMA CORP.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 31, 2026
$1.54−0.05 (-3.14%)
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Nervgen Pharma has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Nervgen Pharma filed with the SEC
NOTICE OF CHANGE OF AUDITOR
EX-99.1 to Form 6-K
Box 10426 777 Dunsmuir Street
EX-99.2 to Form 6-K
Financial and Consumer Affairs Authority of Saskatchewan
EX-99.3 to Form 6-K
(Expressed in Canadian Dollars - Unaudited)
EX-99.1 to Form 6-K
For the three and six months ended June 30,
EX-99.2 to Form 6-K
NervGen Reports Second Quarter 2026 Financial
EX-99.3 to Form 6-K
1301 Avenue of the Americas, 5 th Floor
EX-99.1 to Form 6-K
Name and Address of Company
EX-99.1 to Form 6-K
Positive Independent, Blinded Biomechanical Gait Analyses
EX-99.1 to Form 6-K
Proposed Public Offering of Securities
EX-99.1 to Form 6-K
Pricing of US$60.0 Million Public Offering of Securities
EX-99.2 to Form 6-K
Warrants to Purchase up to 24,000,000 Common Shares
EX-99.3 to Form 6-K
First Quarter 2026 Financial Results and Provides Business Updates
EX-99.1 to Form 6-K
Condensed consolidated interim financial statements of
EX-99.1 to Form 6-K
Management’s Discussion and Analysis of
EX-99.2 to Form 6-K
I, Adam Rogers, Chief Executive Officer of NervGen Pharma Corp., certify
EX-99.3 to Form 6-K
Pharma Strengthens Leadership Team with Appointment
EX-99.1 to Form 6-K
Name and Address of Reporting Issuer
EX-99.2 to Form 6-K
Name and Address of Reporting Issuer
EX-99.1 to Form 6-K
Name and Address of Reporting Issuer
EX-99.1 to Form 6-K